Loading clinical trials...
Loading clinical trials...
The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parki...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Institute for Neurodegenerative Disorders
Collaborators
NCT06193278 · Neuromodulation, Parkinsonian Syndromes, and more
NCT02114242 · Parkinsonian Syndromes, Parkinson's Disease, and more
NCT04974034 · Bradykinesia, Parkinson Disease, and more
NCT00096876 · Parkinson Disease, Parkinsonian Syndrome
NCT00315250 · Parkinson's Disease, Parkinsonian Syndrome
Institute for Neurodegenerative Disorders
New Haven, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions